1 1

Semaglutide (10mg)

Semaglutide (10mg)

$150.00 USD
$150.00 USD
Sale Sold out
Shipping calculated at checkout.

Overview:

Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist, originally developed for the treatment of type 2 diabetes mellitus (T2DM) and now also FDA-approved for obesity management. By mimicking endogenous GLP-1, Semaglutide improves glycemic control, reduces appetite, and promotes significant weight loss.

Marketed under names such as Ozempic® (for T2DM), Rybelsus® (oral version for T2DM), and Wegovy® (for chronic weight management), Semaglutide represents one of the most effective pharmacotherapies for metabolic syndrome, insulin resistance, and cardiometabolic risk reduction.

COA

Third-Party Testing

PubChem Information

https://pubchem.ncbi.nlm.nih.gov/compound/56843331

View full details

What is Semaglutide?

  • Mechanism of Action:

    Semaglutide functions by stimulating the GLP-1 receptor, leading to several beneficial metabolic effects:

    • Enhanced Insulin Secretion: Increases insulin release in a glucose-dependent manner.
    • Suppressed Glucagon Secretion: Reduces inappropriate postprandial glucagon levels.
    • Delayed Gastric Emptying: Slows gastrointestinal motility, promoting satiety and reduced calorie intake.
    • Central Appetite Suppression: Acts on the hypothalamus to decrease hunger and food cravings.

    These mechanisms collectively result in improved glycemic control, weight loss, and reduced cardiovascular risk.

  • Preclinical Studies:

    Obesity (STEP Trials):

    • Up to 15–17% weight reduction at 68 weeks with weekly 2.4 mg injections.
    • Improved body composition with reductions in visceral adiposity.
    • High proportion of patients achieving ≥10% weight loss.

    Type 2 Diabetes (SUSTAIN and PIONEER Trials):

    • Significant HbA1c reduction (1.5–2.1%) in patients with poorly controlled T2DM.
    • Effective as both monotherapy and in combination with other agents.

    Cardiovascular Outcomes:

    • Reduced major adverse cardiovascular events (MACE) in patients with T2DM and existing CVD.
    • Lowered stroke and myocardial infarction incidence.

    Liver Health & NAFLD:

    • Reduction in hepatic steatosis and ALT levels, with emerging interest in NASH treatment.

  • Intended Use:

    • The information provided on this site is intended exclusively for educational and research purposes and should not be interpreted as medical guidance.
    • Research compounds, including Semaglutide, are designed solely for laboratory investigation by qualified professionals and are not intended for human use or consumption.
    • The statements presented here have not been evaluated by the U.S. Food and Drug Administration, and the products discussed are not intended to diagnose, treat, cure, or prevent any disease.